Alumis reported that its TYK2 inhibitor envudeucitinib failed to meet efficacy goals in a key mid-stage lupus study, with investors focusing on the overall population results rather than a prespecified responder subgroup. The company said it sees a path forward toward phase 3 development in patients with an IFN gene signature. Cantor Fitzgerald analyst Eric Schmidt called the outcome “disappointing,” while noting that SLE trials can be volatile. Management’s strategy reflects a continued push across autoimmune drug development to rescue programs through biomarker-defined enrichment after all-comers trials miss. The setback highlights how fragile clinical readouts can be for oral precision immunology—particularly in lupus, where patient heterogeneity drives trial outcomes and partner confidence.